Reportlinker Adds US Therapeutic Apheresis Industry

NEW YORK, Oct. 18 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

US Therapeutic Apheresis Industry

http://www.reportlinker.com/p0315732/US-Therapeutic-Apheresis-Industry.html

This report analyzes the US market for Therapeutic Apheresis in US$ Thousand by the following procedures: Plasmapheresis, Immunoadsorption, Erythrocytapheresis, Plateletpheresis, Leukapheresis, Photopheresis, and Lipidpheresis. The specific end-use segments analyzed are Neurology Disorders, Hematology & Oncology Disorders, Rheumatology Disorders, and Others. Annual estimates and forecasts are provided for the period 2007 through 2015. Also, a six-year historic analysis is provided for this market. The report profiles 18 companies including many key and niche players such as CaridianBCT, Inc., Fenwal, Inc., Fresenius Medical Care North America, Haemonetics Corporation, HemaCare Corporation, Hospital Clinical Services Group, Inc., and Therakos, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

THERAPEUTIC APHERESIS MCP-1237

A US MARKET REPORT

CONTENTS

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Data Interpretation & Reporting Level 3

Quantitative Techniques & Analytics 3

Product Definitions and Scope of Study 3

A Peek into the Above-Mentioned Procedures 4

Plasmapheresis 4

Immunoadsorption 4

Erythrocytapheresis 4

Plateletpheresis 4

Leukapheresis 4

Photopheresis 5

Lipidpheresis 5

2. MARKET ANALYSIS 6

A Current & Future Analysis 6

A Promising Outlook 6

3. MARKET TRENDS 8

Apheresis Process Leads to Rise in Platelet Donors 8

Therapeutic Apheresis Devices - A Perplexing Market 8

Plateletpheresis: The Treatment of Choice for Patients 8

Photopheresis Market Growing at a High Rate 9

Vendors' Attitude Hampers Growth Prospects of Therapeutic

Apheresis 9

Developing New Applications for Therapeutic Apheresis is the

Need of the Hour 10

CFA - An Effective Way to Pull Up Cold Hemagglutinin Disease 10

4. COMPETITIVE SCENARIO 11

Overview 11

Technology: The Only Key for Success 11

CaridianBCT: The World Leader 11

Market Share Trends - A Historic Review 12

By Procedures (Revenues) 12

Table 1: US Market for Therapeutic Apheresis (2002 & 2005):

Percentage Breakdown of Revenues by Company for Gambro BCT,

Therakos, Fresenius Hemocare, Kaneka Pharma America

Corporation, Baxter Transfusion Therapies, and Others

(includes corresponding Graph/Chart) 12

By Procedures (Number of Procedures) 13

Table 2: US Market for Therapeutic Apheresis (2002 & 2005):

Percentage Breakdown of Number of Procedures by Company for

Gambro BCT, Therakos, Fresenius HemoCare, Haemonetics,

Baxter Transfusion Therapies, and Others (includes

corresponding Graph/Chart) 13

By Neurology Disorders (Revenues) 14

Table 3: US Market for Therapeutic Apheresis in Neurological

Disorders (2002 & 2005): Percentage Breakdown of Revenues by

Company for Gambro BCT, Fresenius HemoCare, Haemonetics, and

Others (includes corresponding Graph/Chart) 14

By Neurology Disorders (Number of Procedures) 15

Table 4: US Market for Therapeutic Apheresis in Neurological

Disorders (2002 & 2005): Percentage Breakdown of Number of

Procedures by Company for Gambro BCT, Fresenius HemoCare,

Haemonetics, and Others (includes corresponding Graph/Chart) 15

By Hematology and Oncology Disorders (Revenues) 16

Table 5: US Market for Therapeutic Apheresis in Hematology

and Oncology Disorders (2002 & 2005): Percentage Breakdown

of Revenues by Company for Gambro BCT, Therakos, Fresenius

HemoCare, Baxter Transfusion Therapies, and Others (includes

corresponding Graph/Chart) 16

By Hematology and Oncology (Number of Procedures) 17

Table 6: US Market for Therapeutic Apheresis in Hematology

and Oncology Disorders in (2002 & 2005): Percentage

Breakdown of Number of Procedures by Company for Gambro BCT,

Fresenius HemoCare, Baxter Transfusion Therapies, Therakos,

and Others (includes corresponding Graph/Chart) 17

5. MARKET OVERVIEW & OUTLOOK 18

Market Drivers 18

New Reimbursement Policies Create Growth Opportunities for

Therapeutic Apheresis 18

Increased Industry Consolidation Drives Research 19

Development of New Technology 19

Research Unveils Novel Applications 19

Market Restraints 19

Lack of Awareness Restrains Growth 19

Therapeutic Apheresis Costs Still a Concern 19

Market Challenges 20

Development of Inexpensive Apheresis Therapy 20

Scarcity of Qualified Donors 20

Pediatry: An Untapped Opportunity 20

6. REGULATORY ENVIRONMENT 21

7. PRODUCT OVERVIEW 22

Therapeutic Apheresis: An Introduction 22

Overview of Therapeutic Apheresis 22

Blood Components 22

Apheresis and Therapeutic Apheresis: The Difference 23

Therapeutic Apheresis Process 23

Duration, Frequency, and Efficiency of Therapeutic Apheresis 23

Segregation of Blood Components 23

Centrifugation 24

Filtration 24

History 24

Types of Therapeutic Apheresis Procedures 25

Plasmapheresis 25

Erythrocytapheresis 25

Plateletpheresis 25

Leukapheresis 25

Stem Cell Apheresis 25

Photopheresis 26

Lipidpheresis 26

Cytapheresis 26

Immunoadsorption 26

Rheopheresis 26

Therapeutic Apheresis is Remedial for Various Diseases 27

8. PRODUCT TRENDS AND ISSUES 28

Therapeutic Plasmapheresis with Fresh Frozen Plasma (FFP)

Replacement 28

Risks Associated with Therapeutic Apheresis 28

Categories of Indications for Therapeutic Apheresis 29

Plasma Exchange and Plasmapheresis: The Difference 29

Applications of Plasma Exchange 29

Chronic Diseases 30

Acute Self-Limited Disease 30

Emerging Applications 30

9. PRODUCT AND TECHNOLOGICAL DEVELOPMENTS 31

CaridianBCT Introduces Spectra Optia® System Mononuclear Cell

Collection Protocol 31

Golden Meditech Company to Launch Model 3000H Plasma Exchange

System 31

HemoCleanse to Develop Novel Plasmapheresis Device 31

Aethlon Develops a New Device to Remove HIV 32

Therapeutic Plasmapheresis for Treatment of Autoimmune Diseases 32

Occulogix Offers Blood-Filtering Treatment for Macular

Degeneration 33

10. RECENT INDUSTRY ACTIVITY 34

Therakos Obtains FDA Approval for THERAKOSTM CELLEXTM

Photopheresis System 34

Biotest Acquires Talecris' Plasma Collection Unit 34

Kawasumi Laboratories to Take Over Sales Rights from Kuraray 34

Sheikh Khalifa Medical City Launches Therapeutic Apheresis

Program 34

Asahi Kasei Kuraray Medical to Open New Laboratory 35

Gambro Changes Name to CaridianBCT 35

Therakos Obtains CE Mark in Europe 35

Baxter Divests Transfusion Therapies Business 36

SCSG Gets Hold of Fresenius Medical Care Extracorporeal Alliance 36

Rheologics Technologies Takes Over Cardiodyne Electronics 36

Biotest Obtains Business Unit of Nabi BioPharmaceuticals 36

Gambro BCT Receives FDA Clearance for Spectra Optia System 36

MedaSorb Receives Rights for Blood Processing 37

Fresenius Medical Care Takes Over Renal Care 37

Haemonetics Signs Acquisition Agreement with Arryx 37

Cerus Receives Rights for INTERCEPT Blood System 37

Blood Systems to Implement Gambro BCT 7-day platelets 37

11. STRATEGIC CORPORATE DEVELOPMENTS IN RECENT PAST 38

Renal Care Pockets Bay Area Mobile Apheresis Program 38

Haemonetics Pacts with FMCEA 38

PhereSys and ACGT Ink Consulting Services Pact 38

CHF Forges a Service Provider Pact with FMCEA 38

Otsuka America Inks a Pact with HemaCare 39

Gambro Acquires Ivex 39

Fresenius HemoCare Becomes a Part of Fresenius Kabi 39

Alpha Therapeutic Sells Assets to Probitas Pharma and Baxter 39

Gambro Signs Agreement with The American Red Cross 39

Gambro Receives Contract from NBS 40

FMC-EA Inks Deal with Allina Hospitals 40

Gambro Starts a New Company, Navigant Biotechnologies 40

Gambro's Vista™ Receives Approval from FDA 40

Gambro's New Anticoagulant Solution Receives FDA Approval 40

Gambro BCT Receives FDA Clearance for New Filter Tubing Sets

Developed by Pall 41

Gambro Launches Trima Accel Automated Blood Collection System 41

Fresenius HemoCare Acquires PROSORBA® Column from Cypress

Bioscience 41

Gambro Buys the Assets of Sanguistech 41

Haemonetics Inks Purchase Agreement with Alpha Therapeutic Corp 42

Gambro Joins Forces with the Walter Reed Army Institute of

Research 42

Gambro Collaborates with Dendreon for Commercialization of

Therapeutic Vaccines 42

Gambro AB Enters into a Partnership with Sangart 42

WakeMed Awards a Contract to HemaCare's Subsidiary 43

HemaCare's Subsidiary Coral in Agreement with CMH 43

BioTransplant Inks an Exclusive Distribution Agreement with

Gambro BCT 43

Gambro BCT Receives US Patent for its Pathogen Inactivation

Technology 43

Gambro's Trima Receives Approval from The Japanese Red Cross

Society 44

Gambro BCT Test Launches the Vista™ Information System 44

12. FOCUS ON SELECT PLAYERS 45

CaridianBCT, Inc. 45

Fenwal, Inc. 45

Fresenius Medical Care North America (FMCNA) 45

Haemonetics Corp. 46

HemaCare Corp. 46

Hospital Clinical Services Group, Inc. (HCSG) 46

Therakos, Inc. 47

13. MARKET PERSPECTIVE 48

Table 7: US Recent Past, Current & Future Market Analysis for

Therapeutic Apheresis by Procedure - Plasmapheresis,

Immunoadsorption, Erythrocytapheresis, Plateletpheresis,

Leukapheresis, Photopheresis and Lipidpheresis Markets

Independently Analyzed with Annual Revenues in US$ Thousand

for Years 2007through 2015(includes corresponding Graph/Chart) 48

Table 8: US Historic Review for Therapeutic Apheresis by

Procedure - Plasmapheresis, Immunoadsorption,

Erythrocytapheresis, Plateletpheresis, Leukapheresis,

Photopheresis and Lipidpheresis Markets Independently Analyzed

with Annual Revenues in US$ Thousand for Years 2001 through

2006 (includes corresponding Graph/Chart) 49

Table 9: US 10-Year Perspective for Therapeutic Apheresis by

Procedure - Percentage Breakdown of Revenues for

Plasmapheresis, Immunoadsorption, Erythrocytapheresis,

Plateletpheresis, Leukapheresis, Photopheresis and

Lipidpheresis Markets Independently Analyzed for 2005, 2010 &

2015 (includes corresponding Graph/Chart) 50

Table 10: US Recent Past, Current & Future Market Analysis for

Therapeutic Apheresis by End Use - Neurology Disorders,

Hematology and Oncology Disorders, Rheumatology Disorders and

Other Markets Independently Analyzed with Annual Revenues in

US$ Thousand for Years 2007 through 2010 (includes

corresponding Graph/Chart) 51

Table 11: US Historic Review for Therapeutic Apheresis by

Disorder Type - Neurology, Hematology and Oncology,

Rheumatology and Others Markets Independently Analyzed with

Annual Revenues in US$ Thousand for Years 2001 through 2006

(includes corresponding Graph/Chart) 52

Table 12: US 10-Year Perspective for Therapeutic Apheresis by

End Use - Percentage Breakdown of Revenues for Neurology

Disorders, Hematology and Oncology Disorders, Rheumatology

Disorders and Other Markets Independently Analyzed for 2005,

2010 & 2015 (includes corresponding Graph/Chart) 53

COMPETITIVE LANDSCAPE

Total Companies Profiled: 18 (including Divisions/Subsidiaries - 21)

------------------------------------------

Region/Country Players

------------------------------------------

The United States 17

Europe 4

Germany 3

Rest of Europe 1

------------------------------------------

To order this report:

Therapy Industry: US Therapeutic Apheresis Industry

Therapy Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

SOURCE Reportlinker

21%

more press release views with 

Request a Demo